SCI时时刷

search
+
Best practice and research, clinical endocrinology and metabolism preface to the special issue: Diagnosis and treatment of acromegaly acromegaly, a paradigmatic disease second part: Treatment
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 8a243f300bea5c19-...
Pre-clinical phaeochromocytoma and paraganglioma models: Cell lines, animal models, and a human primary culture model
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 89fc97cc9ecf67f2-...
Best Practice and Research, Clinical Endocrinology and Metabolism Preface to the Special issue: Diagnosis and Treatment of Acromegaly Acromegaly, a paradigmatic disease Second part: Treatment
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 89e2283b3ea015f7-...
Growth hormone receptor antagonist pegvisomant and its role in the medical therapy of growth hormone excess
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 89c7b8a6899367b5-...
Testosterone and other treatments for transgender males and non-binary trans masculine individuals
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 89ad428d09311694-...
The implications of hormone treatment for cancer risk, screening and treatment in transgender individuals
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 89ad42823be19673-...
Metabolic and cardiovascular risks of hormone treatment for transgender individuals
Update your browser to view ScienceDirect. View recommended browsers. Request details: Request ID: 89ad42763c3dfaf0-...
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine
Treatment of acromegaly with the nonpeptide, highly selective somatostatin receptor type 2 agonist paltusotine
Acromegaly is a chronic, systemic disease characterized by high levels of growth hormone (GH) and insulin-like growth fact...
Efficacy and safety of radiosurgery in acromegaly
Efficacy and safety of radiosurgery in acromegaly
Pituitary adenomas originate from the endocrine tissue of the adenohypophysis and are the most common sellar lesions (acco...
Preface to the Special issue: Diagnosis and treatment of acromegaly, a paradigmatic disease
Preface to the Special issue: Diagnosis and treatment of acromegaly, a paradigmatic disease
Cookies are used by this site. Cookie SettingsAll content on this site: Copyright © 2024 Elsevier B.V., its licensors, an...
Preface to the Special issue: Diagnosis and Treatment of Acromegaly Acromegaly, a paradigmatic disease
Preface to the Special issue: Diagnosis and Treatment of Acromegaly Acromegaly, a paradigmatic disease
Cookies are used by this site. Cookie SettingsAll content on this site: Copyright © 2024 Elsevier B.V., its licensors, an...
The molecular biology of sporadic acromegaly
The molecular biology of sporadic acromegaly
Acromegaly/gigantism is characterized by increased levels of growth hormone (GH) and the effector of most of its biologica...
Histopathology of growth hormone-secreting pituitary tumors: state of the art and new perspectives
Histopathology of growth hormone-secreting pituitary tumors: state of the art and new perspectives
Pituitary adenomas (PAs)/Pituitary Neuroendocrine Tumors (PitNETs) are a very heterogenous group of tumors in terms of cli...
Predictors of biochemical response to somatostatin receptor ligands in acromegaly
Predictors of biochemical response to somatostatin receptor ligands in acromegaly
Acromegaly, a rare and subtle condition, frequently escapes early detection, resulting in delayed diagnosis. As a conseque...
Genetic diagnosis in acromegaly and gigantism: from research to clinical practice
Genetic diagnosis in acromegaly and gigantism: from research to clinical practice
It is usually considered that only 5% of all pituitary neuroendocrine tumours are due to inheritable causes. Since this es...
Real-world value of cabergoline in the treatment of acromegaly
Real-world value of cabergoline in the treatment of acromegaly
Acromegaly is a chronic condition caused by a growth hormone (GH)-secreting pituitary adenoma leading to excess production...
Treatment of acromegaly with oral octreotide
Treatment of acromegaly with oral octreotide
Acromegaly is a rare chronic disease caused in most cases by a growth hormone (GH) secreting pituitary adenoma. The estima...
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?
“Micromegaly”: Acromegaly with apparently normal GH, an entity on its own?
Acromegaly is a rare and underdiagnosed disorder caused, in more than 95% of cases, by a growth hormone (GH)-secreting pit...
Surgical outcomes in patients with acromegaly: microscopic vs. endoscopic transsphenoidal surgery
Surgical outcomes in patients with acromegaly: microscopic vs. endoscopic transsphenoidal surgery
Transsphenoidal resection of growth hormone-secreting pituitary neuroendocrine tumors remains the first-line treatment for...
The clinical and biochemical spectrum of ectopic acromegaly
The clinical and biochemical spectrum of ectopic acromegaly
Available online 14 February 2024, 101877Author links open overlay panel, , , , AbstractEctopic acromegaly is a rare condi...
Vitamin D deficiency or resistance and hypophosphatemia
Vitamin D deficiency or resistance and hypophosphatemia
Available online 30 January 2024, 101876Author links open overlay panel, , , AbstractVitamin D is mainly produced in the s...
Current role of pasireotide in the treatment of acromegaly
Current role of pasireotide in the treatment of acromegaly
Available online 24 January 2024, 101875Author links open overlay panel, Abstract“First-generation” somatostatin receptor ...
Primary hyperparathyroidism
Primary hyperparathyroidism
Primary hyperparathyroidism (PHPT), the most common cause of hypercalcemia, is most often identified in postmenopausal wom...
Revisiting Hypophosphatemic rickets/osteomalacia
Revisiting Hypophosphatemic rickets/osteomalacia
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of c...
Premenstrual disorders and PMDD - a review
Premenstrual disorders and PMDD - a review
AbbreviationsPMDDpremenstrual dysphoric disorderMDTmulti-disciplinary teamICDinternational classification of diseasesPMTSp...
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies
Best practice & research clinical endocrinology & metabolism focusing on the menopause – Diagnostic and therapeutic strategies
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of c...
Psychological issues and hormone therapy
Psychological issues and hormone therapy
Premenstrual symptoms have been recognised since Hippocrates in 370AD when menstrual bleeding was thought to purge melanch...
Best Practice & Research Clinical Endocrinology & Metabolism focusing on The Menopause - Diagnostic and Therapeutic Strategies
Best Practice & Research Clinical Endocrinology & Metabolism focusing on The Menopause - Diagnostic and Therapeutic Strategies
We use cookies to help provide and enhance our service and tailor content and ads. By continuing you agree to the use of c...
Menopause: physiology, definitions, and symptoms
Menopause: physiology, definitions, and symptoms
Menopause is a time of transition, with menopausal symptoms often commencing 1–2 years prior to the last menstrual period,...
Post cancer care in women with an increased risk of malignancy or previous malignancy: the use of hormone replacement therapy and alternative treatments.
Post cancer care in women with an increased risk of malignancy or previous malignancy: the use of hormone replacement therapy and alternative treatments.
Nine million women globally are diagnosed with cancer every year, of whom 66% will survive long term in high-income countr...
阅读更多
format_indent_increase